SAN RAMON, Calif., July 12, 2023 (GLOBE NEWSWIRE) -- CooperCompanies (NYSE: COO) today announced that consistent with the plan approved by its board of directors to pay annual dividends, the Company declared a semi-annual dividend of 3 cents per share, payable on August 11, 2023, to stockholders of record on July 27, 2023.
About CooperCompanies
CooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE: COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, CA, Cooper has a workforce of more than 15,000 with products sold in over 130 countries. For more information, please visit www.coopercos.com.
Contact
Kim Duncan
Vice President, Investor Relations and Risk Management
925-460-3663
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$67.40 |
Daily Change: | 2.81 4.35 |
Daily Volume: | 3,854,062 |
Market Cap: | US$13.450B |
August 27, 2025 March 06, 2025 December 17, 2024 |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load